Oncologic research showcased that PPAR-alpha agonists seem to limit the process of angiogenesis, increasing the expression of anti-angiogenic molecules, such as thrombospondin-1 (TSP-1), gypenoside 140 (gp140), and factors involved in the cascade of protein kinases that trigger mitotic divisions of cancer cells [12]. This evidence concerns the gene THBS1 and cancer.